摘要
目的 探讨采用卡前列素氨丁三醇联合米非司酮治疗凶险性前置胎盘的临床疗效。方法 选取陕西省定边县人民医院在2016年1月-12月期间收治的66例中期妊娠胎盘前置引产患者参与研究,随机将患者分为2组,对照组33例,观察组33例。所有患者采用剖宫产的分娩方式,并给予患者催产素和纱条宫腔填塞等传统治疗方式。对照组患者采用米非司酮进行治疗,观察组患者采用卡前列素氨丁三醇联合米非司酮进行治疗。对比2组患者的止血效果和预后2组以及不良反应发生率。结果 经过治疗后,观察组患者的术中出血量和术后2小时阴道出血量、术后2-24小时阴道出血量明显少于对照组患者（P〈0.05）,观察组患者的产后出血率、出现弥散性血管内凝血的概率、发生产褥病的概率明显少于对照组患者（P〈0.05）,血性恶露时间和月经恢复时间均优于对照组患者（P〈0.05）,2组患者的子宫切除率相比无明显差异,2组患者的不良反应发生率比较差异无统计学意义。结论 对凶险性前置胎盘患者采用卡前列素氨丁三醇联合米非司酮治疗,可以有效地降低患者的出血率,有利于促进产妇的康复,安全性高,没有明显的不良反应,值得在临床治疗中进行推广及应用。
Objective Onto observe the curative effect of carboprost tromethamine injection combined with mifepristone on the treatment of the patients with risky placenta previa. Methods 66 cases with placenta previa during mid pregnancy from January 2016 to December 2016 in Dingbian county people＆#39;s hospital were randomly divided into two groups, 33 cases in the control group and 33 cases in the observation group. All patients were received cesarean section and traditional treatments such as oxytocin and gauze filling. Hemostatic effect, prognosis and incidence of adverse reactions in the two groups were compared. Results The intraoperative bleeding volume, the amount of vaginal bleeding 2 hours after operation and the amount of vaginal bleeding 2 to 24 hours after operation in the observation group were less than those in the control group （P〈0.05）. The rate of postpartum hemorrhage, the rate of disseminated intravascular coagulation and the incidence of puerperal disease in the observation group were significantly less than those in the control group （P〈0.05）. The sanguinous lochia time and menstrual recovery time in the observation group were better than those in the control group （P〈0.05）. There was no significant difference in the rate of hysterectomy and adverse reactions between the two groups. Conclusion Carboprost Tromethamine Injection combined with mifepristone in the treatment of pernicious placenta previa can effectively reduce the bleeding rate and promote the rehabilitation of pregnant women. It is safe and has no obvious adverse reactions. It is worthy of clinical application.
出处
《中国生化药物杂志》
CAS
2017年第8期254-256,共3页
Chinese Journal of Biochemical Pharmaceutics
